NCT07545473Recruiting
Retinal Hyperspectral Imaging in Neurodegenerative Diseases
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides a wealth of information about the retinal structure. Our group has developed evidence supporting a role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. We are undertaking further studies to establish the role of this method in the assessment of people with dementia, or those at risk of Alzheimer's disease. In addition, we wish to test whether the approach may have value in other forms of dementia or neurodegenerative disease such as Parkinson's disease, Lewy-Body dementia or vascular dementia.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 930 (estimated)
- First submitted
- 8 Apr 2026
- Start date
- 11 Oct 2021
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Center for Eye Research Australia
- NCT number
- NCT07545473
What you commit to
- Study type: Interventional
- Planned participants: 930
- From 11 Oct 2021 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)
- Any condition that, in the investigator's opinion, would compromise participant safety or image quality
Other
- Inability to provide informed consent
- Known contraindication to pharmacological pupil dilation
Who the study is looking for
- Aged over 30 years.
- Have dementia or a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, Lewy body dementia, Niemann-Pick type 2 or vascular dementia (age-matched and sex-matched controls will also be recruited).
- With the exception of participants with Parkinson's disease and Lewy body disease, for whom clinical examination by a neurologist is sufficient to establish a clinical diagnosis of probable dementia with Lewy Body or probable Parkinson disease dementia, all participants must have previously undergone at least of one of the following tests to help to confirm a clinical diagnosis of dementia or neurodegenerative disease: genetic tests, blood biomarker tests (amyloid, tau, neurofilament light), a brain amyloid beta PET scan, or cerebrospinal fluid tests.
- Have a minimum best corrected visual acuity level of 6/60 in both eyes and no major eye problems, such as advanced age-related macular degeneration, advanced glaucoma, or greater than moderate non-proliferative diabetic retinopathy.
- Be willing to participate in the study and attend the Centre for Eye Research Australia.
- Be accompanied by a friend or family member.
Age in the registry: 30 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Centre for Eye Research Australia Coordinator of this site? Confirm its status | Melbourne | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.